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Abstract
Background:  The morbidity and mortality associated with depression are considerable and
continue to increase. Depression currently ranks fourth among the major causes of disability
worldwide, after lower respiratory infections, prenatal conditions, and HIV/AIDS. Crocus sativus L.
is used to treat depression. Many medicinal plants textbooks refer to this indication whereas there
is no evidence-based document. Our objective was to compare the efficacy of stigmas of Crocus
sativus (saffron) with imipramine in the treatment of mild to moderate depression in a 6-week pilot
double-blind randomized trial.
Methods: Thirty adult outpatients who met the Diagnostic and Statistical Manual of Mental
Disorders, 4th edition for major depression based on the structured clinical interview for DSM IV
participated in the trial. Patients have a baseline Hamilton Rating Scale for Depression score of at
least 18. In this double-blind, single-center trial, patients were randomly assigned to receive capsule
of saffron 30 mg/day (TDS) (Group 1) and capsule of imipramine 100 mg/day (TDS) (Group 2) for
a 6-week study.
Results: Saffron at this dose was found to be effective similar to imipramine in the treatment of
mild to moderate depression (F = 2.91, d.f. = 1, P = 0.09). In the imipramine group anticholinergic
effects such as dry mouth and also sedation were observed more often that was predictable.
Conclusion: The main overall finding from this study is that saffron may be of therapeutic benefit
in the treatment of mild to moderate depression. To the best of our knowledge this is the first
clinical trial that supports this indication for saffron. A large-scale trial with placebo control is
warranted.
Background
Depressive disorders are very common in clinical practice,
with approximately 11.3% of all adults afflicted during
any one year [1]. The majority of patients suffer from mild
Published: 02 September 2004
BMC Complementary and Alternative Medicine 2004, 4:12 doi:10.1186/1472-6882-4-12
Received: 23 April 2004
Accepted: 02 September 2004
This article is available from: http://www.biomedcentral.com/1472-6882/4/12
© 2004 Akhondzadeh et al; licensee BioMed Central Ltd. 
This is an open-access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), 
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.BMC Complementary and Alternative Medicine 2004, 4:12 http://www.biomedcentral.com/1472-6882/4/12
Page 2 of 5
(page number not for citation purposes)
to moderate forms and are treated in primary care settings.
Such patients are often reluctant to take synthetic antide-
pressants in their appropriate doses due to their antici-
pated side effects including inability to drive a car, dry
mouth, constipation and sexual dysfunction. As a thera-
peutic alternative, effective herbal drugs may offer advan-
tages in terms of safety and tolerability, possibly also
improving patient compliance [2,3]. The advent of the
first antidepressants- the Monoamine Oxidase Inhibitors
(MAOIs) and Tricyclic Antidepressants (TCAs) in the
1950s and 1960s represented a dramatic leap forward in
the clinical management of depression. The subsequent
development of the Selective Serotonin Reuptake Inhibi-
tors (SSRIs) and the Serotonin Norepinephrine Reuptake
Inhibitor (SNRI) venlafaxine in the past decade and a half
has greatly enhanced the treatment of depression by offer-
ing patients medications that are as effective as the older
agents but are generally more tolerable and safer in an
overdose [4,5]. The introduction of atypical antidepres-
sants, such as bupropion, nefazadone, and mirtazapine,
has added substantially to the available pharmacopoeia
for depression. Nonetheless, rates of remission tend to be
low and the risk of relapse and recurrence remains high
[2,4]. Thus, there is a need for more effective and less toxic
agents. Plants extracts are some of the most attractive
sources of new drugs, and have been shown to produce
promising results for the treatment of depression [6,7].
Saffron is produced from the tiny, dried stigma of lily-like
Crocus sativus blossom, genuine saffron is worth its weight
in gold. This plant belongs to the Iridaceae family.
Although once considered a remedy for digestive prob-
lems, saffron is no longer used medicinally in the West
[8]. In Asian medicine and in particular Persian tradi-
tional medicine, it is used to treat menstrual disorder, dif-
ficult labor, inflammation, vomiting, and throat diseases
[8-10]. Recent studies indicate its potential as an anti can-
cer and memory enhancer agent as well [11,12]. Although
medicinal plants are used for a wide variety of physical ail-
ments, but often there is limited research supporting these
practices. Crocus sativus is also used to treat depression [9].
Many Persian medicinal plants textbooks refer to this
usage whereas there is no evidence-based document. Our
objective was to compare the efficacy of Crocus sativus with
imipramine in the treatment of mild to moderate depres-
sion in a 6-week double blind randomized trial.
Methods
This was a 6-week randomized and double blind clinical
trial. The investigation was conducted in the outpatient
clinic of Roozbeh Psychiatric Hospital between January
2002 and February 2004.
Patients
Thirty adult outpatients who met the Diagnostic and Sta-
tistical Manual of Mental Disorders, 4th edition (DSM IV)
[13] for major depression based on the structured clinical
interview for DSM IV, participated in the trial. Patients
have a baseline Hamilton Rating Scale for Depression
(HAM-D 17-item) [14] score of at least 18. Prospective
participants with the following DSM IV diagnosis were
excluded: current cognitive disorder in the last year; or
current or past history of bipolar disorder, schizophrenia
and schizotypal personality disorder. Patients were
required to be free of all psychotropic medications for at
least 4 weeks before study entry. Patients were selected to
range in age from 18 to 55 years of age. As depression is a
serious and potentially life threatening condition and the
participants were outpatients so extensive safeguards were
needed. Patients were excluded if they posed a significant
risk of suicide at any time during participation. Persons
who scored greater than 2 on the suicide item of the HAM-
D, or who were judged to have significant suicidal idea-
tion or potential in the view of an investigator were
excluded. Further, any clinically significant deterioration
in the condition of the subject from baseline would result
in exclusion. Those who left the study before completion
were offered alternative and standard care immediately.
Pregnant women or women not using medically accepted
means of birth control were excluded. All participants
provided written informed consent, and the protocol sat-
isfied the Tehran University of Medical Sciences Ethics
Committee requirements.
Saffron capsule preparation
The saffron was used in this study was dedicated by Novin
Zaferan Co (Mashhad, Iran) and was identified by the
Department of Cultivation and Development of Institute
of Medicinal Plants, Tehran, Iran. The stigma's extract was
prepared as follow: 120 g of dried and milled stigmas was
extracted with 1800 ml ethanol (80%) by percolation pro-
cedure in three steps then the ethanolic extract was dried
by evaporation in temperature between 35–40°C. Each
capsule had dried extract of saffron (10 mg), lactose
(filler), magnesium stearate (lubricant), and sodium
starch glycolate (disintegrant).
Study design
Patients underwent a standard clinical assessment com-
prising a psychiatric evaluation, a structured diagnostic
interview and a medical history. Patients were rand-
omized to receive capsule of saffron or capsule of imi-
pramine in a 1: 1 ratio using a computer-generated code.
The investigation preparations were administrated in red
capsules whole indistinguishable in color, size, form and
taste. The assignments were kept in sealed, opaque enve-
lopes until the point of allocation. The randomization
and allocation process was done by the pharmacist of theBMC Complementary and Alternative Medicine 2004, 4:12 http://www.biomedcentral.com/1472-6882/4/12
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Roozbeh Hospital. In this double-blind, single-center
trial, patients were randomly assigned to receive capsule
saffron 30 mg/day (TDS)(Group A) or capsule imi-
pramine 100 mg/day (TDS) for a 6-week study. The dose
of saffron was calculated according to a recent published
animal study [9]. All patients completed the trial. Patients
were assessed by a third year resident of psychiatry at base-
line and after 1, 2, 3, 4 and 6 weeks after the medication
started. The principal measure of the outcome was the 17-
item HAM-D. The rater used standardized instructions in
the use of HAM-D. The mean decrease in HAM-D score
from baseline was used as the main outcome measure of
response of depression to treatment. Throughout the
study the person who administrated the medications,
rater and patients were blind to assignments.
Side effects
Side effects were systematically recorded throughout the
study and were assessed using a checklist administered by
a resident of psychiatry on day 3, 7, 14, 21, 28 and 42
(Table 2).
Statistical analysis
A two-way repeated measures analysis of variance (time-
treatment interaction) was used. The two groups as a
between-subjects factor (group) and the six weekly meas-
urements during treatment as the within-subjects factor
(time) were considered. This was done for HAM-D total
scores. In addition, a one-way repeated measures analysis
of variance with a two-tailed post hoc Tukey mean com-
parison test were performed in the change from baseline
for HAM-D scores in each group. To compare the two
groups at baseline and the outcome of two groups at the
end of the trial, an unpaired Student's t-test with a two-
sided P value was used. Results are presented as mean ±
S.E.M. Differences were considered significant with P <
0.05. To compare the demographic data and frequency of
side effects between the protocols, Fisher's exact test (two
sided) was performed. To consider, a = 0.05, β = 0.2, the
final difference between the two groups at least score of 5
on the HAM-D total scores that is clinically detectable, S =
5 and power = 80%, the sample size was calculated at least
15 in each group.
Results
No significant differences were identified between
patients randomly assigned to the group 1 or 2 conditions
with regard to basic demographic data including age and
gender (Table 1).
Efficacy: Saffron versus imipramine
The mean ± SEM scores of groups 1 and 2 are shown in
Fig. 1. There were no significant differences between the
two groups at week 0 (baseline) on the HAM-D (d.f. = 28,
P = 0.43). Both groups showed a significant improvement
over the 6 weeks of treatment (P < 0.0001). The difference
between the two protocols was not significant as indicated
by the effect of group, the between-subjects factor (F =
2.91, d.f. = 1, P = 0.09). The behavior of the two treatment
groups was homogeneous across the trial (groups-by-time
interaction, F = 0.83, d.f. = 3.44, P = 0.49). In addition, the
difference between the two protocols was not significant
at week 6 (d.f. = 28, P = 0.33).
Table 1: Baseline data
Saffron Group Imipramine Group
Women 98
Man 67
Age (Mean ± SD) 35.53 ± 10.28 (year) 32.53 ± 8.10 (year)
Baseline Hamilton Score 19.20 ± 0.42 19.00 ± 0.44
Table 2: Clinical complications and side effects were reported as number per group.
Side Effects Saffron Imipramine P
Anxiety 4 1 0.32
Decreased Appetite 2 0 0.48
Increased Appetite 1 5 0.16
Sedation 06 0.01
Nausea 2 1 1.00
Headache 3 2 1.00
Dry Mouth 17 0.03
Hypomania 2 1 1.00
Constipation 2 5 038
Urinary Retention 1 5 0.16BMC Complementary and Alternative Medicine 2004, 4:12 http://www.biomedcentral.com/1472-6882/4/12
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Clinical complications and side-effects
A number of probable side effects were studied (Table 2).
Dry mouth and sedation were observed more often in the
imipramine group.
Discussion
The current therapeutic goal in the treatment of major
depression is to improve the quality of life by normalizing
mood, increasing awareness of personal pleasures and
interests, and reversing the functional and social disabili-
ties associated with depression, as well as to reduce sui-
cide rates [1]. Saffron is used in folk medicine as an
antispasmodic, eupeptic, gingival, sedative, anticatarrhal,
nerve sedative, carminative, diaphoteric, expectorant,
stimulant, stomachic, aphrodisiac, antidepressant and
emmenagogue [8]. Furthermore, modern pharmacologi-
cal studies have demonstrated that saffron extract has an
anti tumor effect, radical scavenger property and hypoli-
paemic effect [11]. The present study was carried out to
investigate the possible antidepressant effect of saffron
compared with imipramine that has already shown to be
significantly more efficacious than placebo in the treat-
ment of major depression [2].
In this small preliminary double-blind and randomized
comparison of saffron and imipramine in the treatment of
mild to moderate depression, saffron at this dose was
found to be effective similar to imipramine. Our results
are in the line with a recent published animal study that
Crocus sativus extracts showed antidepressant effect [9]. In
addition, in the imipramine group anticholinergic effects
such as dry mouth and sedation were observed more often
that was predictable. Saffron at this dose did not induce
any abnormal bleeding that is one of the reported side
effects of it. It has been reported that saffron inhibits
platelet adhesion so its use is contraindicated in preg-
nancy [9]. In addition, it has been suggested that crocin
and safranal two major components of saffron inhibit
reuptake of dopamine, norepinephrine and serotonin [9].
The limitations of the present study, including lack of a
placebo group, using only a fixed dose of saffron, the
small number of participants and short period of follow
up should be considered so further research in this area is
needed. Indeed, patients and their families may view
alternative medicine that is, those treatments that are not
traditionally taught in medical schools or generally prac-
ticed by clinicians, as being complementary or even supe-
rior to conventional medicine. In majority of cases there
are no evidence-based documents for them. Therefore, the
search for new and more effective therapeutic agents
includes the scientific study of plants used in traditional
medicine systems to treat mental disorders. The main
overall finding from this study is that saffron may be of
therapeutic benefit in the treatment of mild to moderate
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